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Faecal microRNAs as a non-invasive 
tool in the diagnosis of colonic 
adenomas and colorectal cancer: A 
meta-analysis
tung on Yau  1, Ceen-Ming tang2, elinor K. Harriss3, Benjamin Dickins  1 & 
Christos polytarchou  1
MicroRNAs (miRNAs) are proposed as potential biomarkers for the diagnosis of numerous diseases. 
Here, we performed a meta-analysis to evaluate the utility of faecal miRNAs as a non-invasive tool in 
colorectal cancer (CRC) screening. A systematic literature search, according to predetermined criteria, 
in five databases identified 17 research articles including 6475, 783 and 5569 faecal-based miRNA 
tests in CRC, adenoma patients and healthy individuals, respectively. Sensitivity, specificity, positive/
negative likelihood and diagnostic odds ratios, area under curve (AUC), summary receiver operator 
characteristic (sRoC) curves, association of individual or combinations of miRNAs to cancer stage and 
location, subgroup, meta-regression and Deeks’ funnel plot asymmetry analyses were employed. 
Pooled miRNAs for CRC had an AUC of 0.811, with a sensitivity of 58.8% (95% confidence interval [CI]: 
51.7–65.5%) and specificity of 84.8% (95% CI: 81.1–87.8%), whilst for colonic adenoma, it was 0.747, 
57.3% (95% CI: 40.8–72.3%) and 76.1% (95% CI: 66.1–89.4%), respectively. The most reliable individual 
miRNA was miR-21, with an AUC of 0.843, sensitivity of 59.3% (95% CI: 26.3–85.6%) and specificity 
of 85.6% (95% CI: 72.2–93.2%). Paired stage analysis showed a better diagnostic accuracy in late stage 
CRC and sensitivity higher in distal than proximal CRC. In conclusion, faecal miR-21, miR-92a and their 
combination are promising non-invasive biomarkers for faecal-based CRC screening.
Colorectal cancer (CRC) is the second leading cancer-related cause of death in the United Kingdom (UK) and 
accounts for over 500,000 deaths annually worldwide1. The pathogenesis of CRC follows a protracted stepwise 
progression from benign colonic adenomas to malignant adenocarcinomas and distant metastasis. Patient sur-
vival inversely correlates to cancer stage during diagnosis, with up to 90% of deaths avertable if detected early2. 
However, CRC is often asymptomatic in its early stage and arises sporadically within the population, posing a 
challenge to the application of effective and timely treatments3. The mass screening of asymptomatic individuals 
for CRC utilising a non-invasive method is thus a high public health priority.
Under the National Health Service (NHS) Bowel Cancer Screening Program in the UK, currently, the faecal 
immunochemical test (FIT) is offered every two years to all asymptomatic men and women aged 60 to 744. The 
FIT, which examines faecal samples for hidden blood, is appealing because the costs are low, the test is widely 
available, and does not pose an immediate risk to the screened population5. Although the recent changes from 
Faecal Occult Blood Test (FOBT) to FIT has improved the screening power by specific targeting to human hae-
moglobin, the effectiveness of FIT is still restricted by its relatively low sensitivity, with about half of all malignant 
large bowel tumours and most polyps undetected. This is due to the intermittent nature of bleeding6 as well as 
degradation of haemoglobin in faeces7. Consequently, one in four CRC cases is only diagnosed at a late stage on 
emergency admission, resulting in poor prognosis8. Therefore, a more sensitive faecal-based non-invasive test is 
urgently needed.
miRNAs are a class of conserved endogenous, short non-coding RNAs with length of 18–24 nucleotides. miR-
NAs regulate gene expression through post-transcriptional processing by binding primarily to the 3′-untranslated 
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region (3′UTR) of target mRNAs, resulting in mRNA degradation and/or translational repression9. Specific miR-
NAs (oncomiRs) through targeting tumour-suppressor genes have been found to be upregulated, while oth-
ers targeting oncogenes are downregulated, in cancer. These alterations, through the regulation of intracellular 
signalling networks, induce cell proliferation, confer resistance to apoptosis and chemotherapy, and promote 
metastasis10. The expression of several miRNAs differs significantly between normal colonic tissues and CRC, 
and as colonocytes consistently exfoliate and shed into the lumen of the gastrointestinal (GI) tract, these changes 
in miRNA levels are represented in faecal specimens11–27. More recently, it was demonstrated that miRNAs are 
highly stable and detectable within samples throughout a 72 hour incubation period due to protection from rib-
onuclease degradation by exosomes28,29. Given that faeces contain genomic DNA and RNA derived from gut 
microbes, and miRNAs derived from blood cells released by tumours, the detection and utility of miRNAs for 
diagnostic purposes has been controversial. Therefore, this meta-analysis aims to assess the value of miRNAs as 
faecal-based biomarkers for CRC and colonic adenoma screening.
Results
Characteristics of selected studies. The initial literature search from five different databases yielded a 
total of 567 articles, of which 249 were excluded as duplicated records. Next, 165 articles were deemed irrelevant 
and excluded based on the title and abstract. The full-text of the remaining publications were screened, resulting 
in the inclusion of 17 publications (16 in English, 1 in Chinese) (Fig. 1). These publications contained 46 studies 
on CRC and 10 studies on adenomas, corresponding to 6475, 783 and 5569 faecal-based miRNA tests in CRC 
patients, adenoma and healthy controls, respectively (Tables 1 and 2). The clinical data and collection procedures 
are summarised in Suppl. Table 1A,B, and methods of miRNA extraction and quantification in Suppl. Table 2A,B.
Risk of bias. All included articles were evaluated for the risk of bias using the QUADAS-2 tool (Fig. 2)30. The 
major risk of bias in this study was in the index test, where 10 out of 17 publications had a high risk of bias due 
to the unclear or lack of statement regarding interpretation of index test results without knowledge of the results 
of the reference. Additionally, 14 out of 17 studies had an unclear risk of bias in the “Patient Selection” domain. 
This is due to a lack of detail on whether a consecutive or random sample of patients were enrolled. There was a 
Figure 1. Flowchart diagram of study selection based on the inclusion and exclusion criteria.
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low risk of bias in the reference standard, since all studies were histopathologically confirmed prior to the index 
test using either TNM or Dukes’ staging (Suppl. Table 1A,B). Concern about applicability in all domains was low.
pooled diagnostic accuracy of faecal-based microRNA for colorectal cancer and adenoma. The 
detection accuracy of faecal-based miRNAs for CRC (Table 3) as well as colonic adenoma (Table 4) were pooled 
and analysed using the bivariate random effects model to evaluate the overall diagnostic measurements (Fig. 3). 
The DOR and log DOR were 8.32 (95% CI: 6.71–10.32) and 2.12 (95% CI: 1.90–2.33) for CRC and 5.31 (95% 
CI: 3.55–7.94) and 1.67 (95% CI: 1.27–2.07) for adenoma, respectively. The AUC value was 0.811 for the pooled 
Study 
ID
First author (Year)
[Reference no.]
Origin of 
population
Sample size
miRNA profile
qPCR quantitation 
method
Proximal/
Distal
Early/Late 
stageCRC Control
1 Koga Y (2010)11 Japan 119 197 miR-17-92 cluster* Relative Y Y
2 Koga Y (2010)11 Japan 119 197 miR-17 Relative — —
3 Koga Y (2010)11 Japan 119 197 miR-18a Relative — —
4 Koga Y (2010)11 Japan 119 197 miR-19a Relative — —
5 Koga Y (2010)11 Japan 119 197 miR-19b Relative — —
6 Koga Y (2010)11 Japan 119 197 miR-20a Relative — —
7 Koga Y (2010)11 Japan 119 197 miR-92a Relative — —
8 Koga Y (2010)11 Japan 119 197 miR-21 Relative Y Y
9 Koga Y (2010)11 Japan 119 197 miR-135a, miR-135b Relative Y Y
10 Koga Y (2010)11 Japan 119 197 miR-135a Relative — —
11 Koga Y (2010)11 Japan 119 197 miR-135b Relative — —
12 Koga Y (2010)11 Japan 119 197 miR-17-92 cluster*, miR-21, miR-135a/b Relative Y Y
13 Kalimutho M (2011)12 Italy 40 35 miR-144-5p Relative — —
14 Wu CW (2012)20 Hong Kong 101 88 miR-21 Absolute Y Y
15 Wu CW (2012)20 Hong Kong 101 88 miR-92a Absolute Y Y
16 Wu CW (2012)20 Hong Kong 101 88 miR-21, miR-92a Absolute Y Y
17 Kuriyama S (2012)21 Japan 126 138 miR-106a Relative — —
18 Kuriyama S (2012)21 Japan 126 138 miR-21, miR-92a, miR-106a Relative — —
19 Kanaoka S (2013)22 Japan 126 138 miR-21 Relative — —
20 Kanaoka S (2013)22 Japan 126 138 miR-92a Relative — —
21 Koga Y (2013)23 Japan 107 117 miR-106a Relative — —
22 Zhao HJ (2014)24 China 20 28 miR-194 Relative — —
23 Wu CW (2014)25 Hong Kong 109 104 miR-135b Absolute — —
24 Yau TO (2014)26 Hong Kong 198 198 miR-221 Absolute — —
25 Yau TO (2014)26 Hong Kong 198 198 miR-18a Absolute — —
26 Yau TO (2014)26 Hong Kong 198 198 miR-221, miR-18a Absolute — —
27 Yau TO (2014)26 Hong Kong 198 198 miR-221, miR-135b Absolute — —
28 Yau TO (2014)26 Hong Kong 198 198 miR-18a, miR-135b Absolute — —
29 Yau TO (2014)26 Hong Kong 198 198 miR-221, miR-18a, miR-135b Absolute — —
30 Phua LC (2014)27 Singapore 28 17 miR-223 Relative — —
31 Phua LC (2014)27 Singapore 28 17 miR-451 Relative — —
32 Chang PY (2016)13 Taiwan 309 138 miR-223, miR-92a, miR-16, miR-106b Relative — —
33 Chang PY (2016)13 Taiwan 309 138 miR-223, miR-92a Relative — —
34 Yau TO (2016)14 Hong Kong 198 198 miR-20a Absolute — —
35 Yau TO (2016)14 Hong Kong 198 198 miR-20a, miR-92a Absolute — —
36 Yau TO (2016)14 Hong Kong 198 198 miR-20a, miR-135b Absolute — —
37 Zhu Y (2016)15 China 51 80 miR-29a Relative — —
38 Zhu Y (2016)15 China 51 80 miR-223 Relative — —
39 Zhu Y (2016)15 China 51 80 miR-224 Relative — —
40 Liu H (2016)16 China 150 98 miR-21 Relative — —
41 Liu H (2016)16 China 150 98 miR-146a Relative — —
42 Liu H (2016)16 China 150 98 miR-21, miR-146a Relative — —
43 Xue Y (2016)17 China 50 50 miR-141 Relative — —
44 Xue Y (2016)17 China 50 50 miR-92a Relative — —
45 Bastaminejad S (2017)18 Iran 40 40 miR-21 Relative — —
46 Wu CW (2017)19 USA 29 115 miR-451a, miR-144-5p Relative Y Y
Table 1. All publications on faecal-based microRNAs for the detection of colorectal cancer. *The miR-17-92 
cluster includes miR-17, miR-18a, miR-19a, miR-20a, miR-19b-1, and miR-92a.
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CRC, and 0.747 for the pooled adenoma, respectively. The pooled studies of miRNAs in identification of CRC 
had a sensitivity of 58.8% (95% CI: 51.7–65.5%) and specificity of 84.8% (95% CI: 81.1–87.8%), whilst the pooled 
studies of miRNAs for identification of adenoma had a sensitivity of 57.3% (95% CI: 40.8–72.3%) and specificity 
of 76.1% (95% CI: 66.1–89.4%).
Relative quantitation has a higher detection accuracy in colorectal cancer screening. To inves-
tigate the potential of faecal-based miRNA in the non-invasive diagnosis of CRC, studies were subgrouped in 
different aspects to compare their detection accuracy (Table 3). For the individual/combination miRNA anal-
ysis, both presented a similar power of diagnostic accuracy. The individual miRNA analysis panel had a sen-
sitivity of 53.5% (95% CI: 43.8–62.9%), specificity of 86.4% (95% CI: 81.8–89.9%), DOR of 7.71 (5.65–10.52), 
and log DOR of 2.04 (95% CI: 1.73–2.35). The combination of miRNAs had a sensitivity of 68.8% (95% CI: 
63.0–74.0%), specificity of 81.6% (95% CI: 75.0–86.8%), DOR of 9.73 (95% CI: 7.51–12.60), and log DOR of 
2.28 (95% CI: 2.02–2.53). The AUC value was 0.808 for the individual miRNAs, and 0.801 for the combination 
of miRNAs, respectively. The meta-regression analysis showed a significant effect on pooled sensitivity (Z-value: 
2.310, P = 0.021) but not in specificity (Z-value: 1.28, P = 0.199) (Table 4). Comparing studies with large (n > 100) 
versus small size (n ≤ 100), there was a sensitivity of 53.4% (95% CI: 44.4–62.3%) versus 70.6% (95% CI: 64.2–
76.3%), specificity of 86.3% (95% CI: 82.3–89.6%) versus 80.8% (95% CI: 72.3–87.1%), DOR of 7.83 (95% CI: 
6.11–10.04) versus 10.16 (95% CI: 6.45–16.00) and AUC of 0.811 versus 0.801 respectively. The meta-regression 
analysis indicated that the sample size did not significantly affect the pooled specificity (Z-value: 1.601, P = 0.109), 
however it did affect the pooled sensitivity (z-value: 2.458, P = 0.014).
The quantitation methods of absolute versus relative qPCR for faecal-based miRNAs were compared. The 
pooled relative quantitation qPCR method exhibited a better diagnostic accuracy in CRC (Table 3), with a sen-
sitivity of 55.5% (95% CI: 45.9–64.7%), specificity of 88.8% (95% CI: 85.2–91.6%), DOR of 10.738 (95% CI: 
7.718–14.940), log DOR of 2.37 (95% CI: 2.04–2.70) and AUC of 0.846. By contrast, the pooled absolute quanti-
tation qPCR method exhibited sensitivity, specificity, DOR, log DOR and AUC of 67.3% (95% CI: 62.3–71.9%), 
69.2% (95% CI: 69.4–77.0%), 5.706 (95% CI: 4.937–6.594), 1.74 (95% CI: 1.06–1.89) and 0.763, respectively. The 
meta-regression analysis revealed that the qPCR relative quantitation method in CRC affected only specificity 
(Z-value = −4.317, P < 0.001) when compared to the absolute quantification approach. The pooled relative quan-
titation qPCR approach exhibited a DOR of 8.32 (95% CI: 5.55–12.48) and log DOR of 2.12 (95% CI: 1.71–2.52) 
Study 
ID
First author (Year)
[Reference no.]
Origin of 
population
Sample size
miRNA profile
qPCR quantitation 
methodAdenoma Control
I Wu CW (2012)20 Hong Kong 57 88 miR-21 Absolute
II Wu CW (2012)20 Hong Kong 57 88 miR-92a Absolute
III Wu CW (2012)20 Hong Kong 57 88 miR-21, miR-92a Absolute
IV Kanaoka S (2013)22 Japan 26 138 miR-21 Relative
V Kanaoka S (2013)22 Japan 26 138 miR-92a Relative
VI Wu CW (2014)25 Hong Kong 169 104 miR-135b Absolute
VII Liu H (2016)16 China 120 98 miR-21 Relative
VIII Liu H (2016)16 China 120 98 miR-146a Relative
IX Liu H (2016)16 China 120 98 miR-21, miR-146a Relative
X Wu CW (2017)19 USA 31 115 miR-451a, miR-144-5p Relative
Table 2. All publications on faecal-based microRNAs for the detection of colonic adenomas.
Figure 2. Quality assessment of included studies utilising the Quality Assessment of Diagnostic Accuracy 
Studies (QUADAS) version 2. Summary of risk of bias and applicability concerns for faecal-based miRNAs in 
the detection of colorectal cancer.
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with a specificity of 86.7% (95% CI: 67.6–95.3%) and sensitivity of 56.9% (95% CI: 31.4–79.2%), compared with 
the absolute quantification approach (Table 3 and Suppl. Fig. 1).
Subgroup meta-regression analysis in colonic adenoma was also performed, looking at differences in sample 
size, pooled individual/combination miRNAs and quantitation method (Table 4). The meta-regression indicated 
that a small sample size significantly affected both the specificity (Z-value: −2.011, P = 0.044) and sensitivity 
(Z-value: −1.309, P < 0.001). With respect to the pooled individual/combination miRNAs, meta-regression anal-
ysis did not show significant effects in both the pooled sensitivity (Z-value: −10.85, P = 0.853) and specificity 
(Z-value: −0.194, P = 0.846). For the qPCR relative quantitation method, a significant effect was observed in the 
sensitivity (Z-value = −3.356, P < 0.001) of pooled miRNAs.
Differences in detecting CRC depending on tumour stage and location. Meta-analysis on early 
versus late stage CRC as well as proximal versus distal CRC were performed to further evaluate the diagnostic 
ability of miRNAs. Pooled faecal miRNAs had a sensitivity of 57.0% (95% CI: 44.4–68.8%), specificity of 80.0% 
(95% CI: 71.1–86.7%), DOR of 5.58 (95% CI: 3.62–8.62) and log DOR of 1.72 (95% CI: 1.29–2.15) with respect 
to the diagnosis of early stage CRC, whilst in late stage CRC pooled miRNAs had a sensitivity of 62.1% (95% CI: 
No. of 
Studies AUC
Partial 
AUC
log DOR 
(95% CI) DOR (95% CI)
Sensitivity 
(95% CI)
Specificity 
(95% CI)
+LR  
(95% CI)
−LR  
(95% CI)
Meta-Regression
Sensitivity 
Z-value, P
Specificity 
Z-value, P
Pooled miRNAs for 
CRC 46 0.811 0.624
2.12 
(1.90–2.33)
8.32  
(6.71–10.32)
58.8% 
(51.7–65.5%)
84.8% 
(81.1–87.8%)
3.34 
(2.93–3.81)
0.47 
(0.42–0.53) — —
Sample size
Small (Case n < 100) 14 0.801 0.681 2.32 (1.86–2.77)
10.16 
(6.45–16.00)
70.6% 
(64.2–76.3%)
80.8% 
(72.3–87.1%)
3.38 
(2.52–4.52)
0.38 
(0.32–0.46)
2.458, P = 0.014 1.601, P = 0.109
Large (Case n > 100) 32 0.811 0.561 2.06 (1.81–2.31)
7.83  
(6.11–10.04)
53.4% 
(44.4–62.3%)
86.3% 
(82.3–89.6%)
3.36 
(2.90–3.90)
0.51 
(0.45–0.57)
Pooled individual / Combination miRNAs
Individual miRNA 31 0.808 0.593 2.04 (1.73–2.35)
7.71  
(5.65–10.52)
53.5% 
(43.8–62.9%)
86.4% 
(81.8–89.9%)
3.32 
(2.76–4.00)
0.54 
(0.48–0.60)
2.310, P = 0.021 1.284, P = 0.199
Combination miRNAs 15 0.801 0.674 2.28 (2.02–2.53)
9.73  
(7.51–12.60)
68.8% 
(63.0–74.0%)
81.6% 
(75.0–86.8%)
3.47 
(2.87–4.20)
0.39 
(0.34–0.44)
Quantitation method
Absolute 13 0.763 0.685 1.74 (1.06–1.89)
5.706  
(4.937–6.594)
67.3% 
(62.3–71.9%)
69.2% 
(69.4–77.0%)
2.49 
(2.26–2.74)
0.46 
(0.41–0.51)
−1.632, P = 0.103 −4.317, P < 0.001
Relative 33 0.846 0.662 2.37 (2.04–2.70)
10.738  
(7.718–14.940)
55.5% 
(45.9–64.7%)
88.8% 
(85.2–91.6%)
4.27 
(3.48–5.23)
0.49 
(0.43–0.55)
Table 3. Subgroup analysis for pooled microRNAs in the identification of CRC. AUC, Area under curve; DOR, 
Diagnostic odds ratio; +LR, Positive likelihood ratio; −LR = Negative likelihood ratio; Z-value, regression 
coefficient. P < 0.05 was considered statistically significant.
No. of 
Studies AUC
Partial 
AUC
log DOR 
(95% CI)
DOR (95% 
CI)
Sensitivity 
(95% CI)
Specificity 
(95% CI)
+LR  
(95% CI)
−LR  
(95% CI)
Meta-Regression
Sensitivity 
Z-value, P
Specificity 
Z-value, P
Pooled miRNAs for Adenoma 10 0.747 0.560 1.67 (1.27–2.07)
5.31 
(3.55–7.94)
57.3% 
(40.8–72.3%)
76.1% 
(66.1–89.4%)
2.28 
(1.84–2.84)
0.53 
(0.41–0.68) — —
Sample size
Small (Case n < 100) 4 0.647 0.490 1.53 (0.86–2.20)
6.36 
(4.35–9.31)
42.0% 
(27.5–58.1%)
87.7% 
(70.0–95.6%)
2.23 
(1.93–2.57)
0.35 
(0.25–0.49) −1.309 
P < 0.001
−2.011 
P = 0.044
Large (Case n > 100) 6 0.701 0.779 1.85 (1.47–2.23)
4.63 
(2.37–9.04)
77.0% 
(67.7–84.2%)
65.7% 
(70.5–85.9%)
2.87 
(1.71–4.83)
0.71 
(0.59–0.85)
Pooled individual/Combination miRNAs
Individual miRNA 7 0.749 0.566 1.78 (1.26–2.30)
5.93 
(3.52–10.00)
58.7% 
(41.6–73.9%)
81.6% 
(63.6–91.8%)
2.50 
(1.86–3.36)
0.52 
(0.40–0.67) −0.185 
P = 0.853
−0.194 
P = 0.846
Combination miRNAs 3 0.729 0.520 1.45 (0.73–1.17)
4.26 
(2.07–8.76)
52.6% 
(13.4–88.8%)
78.1% 
(42.2–94.5%)
1.97 
(1.45–2.67)
0.55 
(0.28–1.09)
Quantitation method
Absolute 4 0.687 0.626 1.16 (0.84–1.47)
3.18 
(2.33–4.35)
59.4% 
(48.0–69.9%)
68.2% 
(36.7–52.0%)
1.83 
(1.54–2.16)
0.61 
(0.50–0.74) −3.356 
P = 0.001
−1.859 
P = 0.063
Relative 6 0.802 0.622 2.12 (1.71–2.52)
8.32 
(5.55–12.48)
56.9% 
(31.4–79.2%)
86.7% 
(67.6–95.3%)
3.01 
(2.09–4.34)
0.48 
(0.31–0.73)
Table 4. Subgroup analysis for pooled microRNAs in the identification of adenomas. AUC, Area under curve; 
DOR, Diagnostic odds ratio; +LR, Positive likelihood ratio; −LR, Negative likelihood ratio; Z-value, regression 
coefficient. P < 0.05 was considered as statistically significant.
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Figure 3. Diagnostic accuracy of pooled microRNAs in identification of colorectal cancer and colonic 
adenoma. Log Diagnostic Odds radios in (A) CRC was 2.12 (95% CI: 1.90–2.33) and (B) adenoma was 1.67 
(95% CI: 1.27–2.07). (C) Summary receiver operating characteristic curves (SROC) for pooled miRNAs in CRC 
and colonic adenoma. The pooled miRNAs for CRC (n = 46) had a sensitivity of 58.8% (95% CI: 51.7–65.5%), 
specificity of 84.8% (95% CI: 81.1–87.8%) and AUC of 0.811. The pooled miRNAs for adenoma (n = 10) had 
a sensitivity of 57.3% (95% CI: 40.8–72.3%), specificity of 76.1% (95% CI: 66.1–89.4%) and AUC of 0.747. 
The number next to the dot/triangle corresponds to the study ID in Table 1 (Blue dots: CRC) or Table 2 (Red 
triangles: colonic adenoma). The circular regions (95% confidence contour) contain likely combinations of the 
mean value of sensitivity and specificity. Sen, sensitivity; Spe, specificity; SOP, summary operating point.
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47.8–74.6%), specificity of 80.0% (95% CI: 71.1–86.7%), DOR of 6.70 (95% CI: 4.34–10.36) and log DOR of 1.90 
(95% CI: 1.47–2.34) (Fig. 4A,B and Table 5). In proximal CRC, the pooled sensitivity, specificity, DOR, log DOR 
and AUC were 39.8% (95% CI: 21.8–61.0%), 82.4% (95% CI: 71.5–89.7%), 3.44 (95% CI: 2.53–4.66), 1.23 (95% 
CI: 0.93–1.54) and 0.719, respectively. For distal CRC, the pooled sensitivity, specificity, DOR, log DOR and 
AUC were 64.1% (95% CI: 43.9–80.3%), 81.9% (95% CI: 71.5–89.1%), 8.51 (95% CI: 4.97–14.57), 2.14 (95% CI: 
1.60–2.68) and 0.818, respectively (Table 6 and Suppl. Fig. 2).
the detection accuracy of individual microRNAs. Each individual miRNA reported by more than one 
research group was pooled for an accuracy estimation (Table 6). miR-21 was reported by five CRC and three colonic 
adenoma studies11,16,18,20,22. Pooled miR-21 in CRC had an AUC of 0.843, DOR of 9.28 (95% CI: 2.97–28.97) and log 
DOR of 2.23 (95% CI: 1.09–3.37) whilst pooled miR-21 in adenoma had an AUC of 0.771, DOR of 7.10 (96% CI: 1.99–
25.34) and log DOR of 1.96 (96% CI: 1.96–3.23) (Fig. 5A and Table 6). The miR-21-related combination pool for CRC 
detection had an AUC of 0.843, with a DOR of 16.73 (95% CI: 7.00–39.94) and log DOR of 2.82 (95% CI: 1.95–3.69) 
from four different CRC studies. miR-92a was reported in four CRC and two adenoma studies11,20–22. The AUC, DOR 
and log DOR were 0.794, 8.57 (95% CI: 3.30–22.27) and 2.15 (95% CI: 1.19–3.10) for pooled miR-92a alone in the 
diagnosis of CRC, and 0.635, 0.467, 7.08 (95% CI: 1.43–34.97) and 1.96 (95% CI: 0.36–3.55) for pooled miR-92a alone 
in the diagnosis of colonic adenoma, respectively (Fig. 5B and Table 6).
The miR-92a-related combination pool for CRC was reported in five CRC studies, with AUC 0.791, DOR 10.47 
(95% CI: 6.46–16.98) and log DOR 2.35 (95% CI: 1.87–2.83). The pooled miR-21 plus miR-92a combination exhibited 
an AUC of 0.837, with a specificity of 87.8% (95% CI: 79.5–93.0%), sensitivity of 53.7% (95% CI: 33.4–74.8%) and DOR 
of 2.19 (95% CI: 1.48–2.91). miR-20a, miR-106a, miR-135b and miR-223 were reported in two different articles, with an 
AUC of 0.797, 0.416, 0.798 and 0.777, DOR of 3.87 (95% CI: 1.75–8.55), 29.33 (95% CI: 7.74–111.11), 10.18 (95% CI: 
4.91–21.09) and 14.69 (95% CI: 0.66–328.44), respectively (Table 6 and Suppl. Fig. 2).
publication bias evaluation. The Deeks’ funnel plot asymmetry test was utilised to evaluate the potential 
publication bias from each included faecal-based miRNA study. The slope coefficient was associated with P = 0.03 
in the pooled miRNAs in CRC, and P = 0.61 in pooled miRNAs in colonic adenoma studies, indicating that sig-
nificant asymmetry was found in the CRC dataset (Fig. 6A) but not in the colonic adenoma dataset (Fig. 6B). The 
combination of CRC and colonic adenoma resulted in a P = 0.11 (Suppl. Fig. 3).
Discussion
To evaluate the diagnostic value of faecal-based miRNAs, data from 17 eligible publications, including 46 stud-
ies on miRNAs in CRC and 10 studies on colonic adenoma, corresponding to 6475, 783 and 5569 faecal-based 
miRNA tests in CRC patients, adenoma and healthy control volunteers, respectively, were subjected to 
meta-analysis. Our study reveals that pooled faecal-based miRNAs have a relatively high detection accuracy for 
Figure 4. Diagnostic accuracy in early stage versus late stage and proximal versus distal colorectal cancer. (A) 
Summary receiver operating characteristic curves (SROC) for early (n = 11) and late (n = 11) stage CRC. (B) 
SROC for proximal (n = 9) and distal (n = 9) CRC. The number next to the blue dot/red triangle corresponds to 
the study ID in Table 1. The circular regions (95% confidence contour) contain likely combinations of the mean 
value of sensitivity and specificity. Sen = sensitivity; Spe = specificity SOP, summary operating point. #Early 
stage CRC includes TMN stages 0 + I + II or Dukes’ stage A + B; late stage CRC includes CRC stages III + IV or 
Dukes’ stage C + D. Proximal CRC is defined as from cecum to transverse colon, and distal CRC is defined as 
from the splenic flexure to the rectum.
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CRC. However, the lack of consensus regarding the optimal quantitation method, data normalisation, and selec-
tion of control subjects, may present obstacles to clinical application.
qPCR-based studies were the subject of our meta-analysis analysis. This approach for miRNA level quanti-
fication is advantageous compared to others in that is fast and easily adoptable in a clinical setting. However, it 
comes with limitations that relate to the method for miRNA isolation and the selection of the appropriate refer-
ence/normalisation control. Although reference quantitation method demonstrated a better diagnostic accuracy 
compared to absolute quantitation, it is important to acknowledge that a variety of internal controls were used 
as references, including RUN6B(U6)11,15–18,24, miR-2423, miR-200b-3p19, miR-37812, miR-120227 and miR-425727. 
Increasing evidence suggests that RUN6B may not be a suitable endogenous control for miRNAs31,32 due to its 
rapid degradation in faeces20. miRNAs used as internal controls also have functions in the host cell, and their 
deregulation could interfere with the detection accuracy. For example, miR-24, a proposed tumour suppressor 
miRNA in CRC, controls cellular proliferation independently of p53 by targeting the 3’UTR of dihydrofolate 
reductase (DHFR) mRNA33,34. Deregulation of plasma miR-378 was also found in CRC patients35. miR-4257 
has been reported to be down-regulated in bladder cancer cell lines and up-regulated in the plasma of patients 
with recurrence of non-small cell lung cancer (NSCLC)36,37. Peripheral levels of miR-1202 predicts and medi-
ates the response to anti-depressants, specifically regulating the expression of metabotropic glutamate receptor-4 
(GRM4) with levels correlating to changes in brain activity38–40. miR-1202 is deregulated in different types of can-
cers, such as breast cancer41, gastric cancer42 and clear cell papillary renal cell carcinoma43. Absolute quantitation 
was employed in several studies for faecal-based miRNA screening13,14,20,26 (Table 1), however, this necessitates a 
standard curve which depends on the quantification detection method and does not eliminate potential contam-
ination by gut bacteria DNA/RNA14.
The combination of FIT and stool-based miRNA markers may increase detection accuracy to overcome this 
problem. A previous study indicated that the combination of miR-21 and miR-92a with FIT had a specificity of 
96.8% and sensitivity of 78.4% while FIT alone only had a specificity of 98.4% and sensitivity of 66.7%22. A param-
eter that should be considered is the presence/absence of occult blood in samples as miRNAs expressed in blood 
cells may interfere with the assay, altering the levels of specific miRNAs. In an effort to assess the potential con-
tribution of blood in faecal miRNA levels we have retrieved a list of circulating miRNAs44. Comparison showed 
that 8 miRNAs are detected in both blood and faecal specimens (Suppl. Fig. 4). This finding does not imply that 
blood cells are responsible for the alterations in the levels of these miRNAs, as their origin may as well be the 
tumour. Optimally, a controlled study including comparisons between samples positive and negative for FOBT/
FIT could address the relative contribution. A more inclusive approach employing miRNA analyses and compar-
isons between matched blood, faecal specimens and tumours or colonic tissues would be most informative about 
the source of changes in miRNA levels. Furthermore, other colonic pathologies like inflammatory bowel diseases 
are characterised by deregulation of miRNAs detectable in tissues and serum45–48 and the presence of occult blood 
in faeces. A comprehensive analysis would include samples from different pathologies of the colon, assess and 
identify disease-specific miRNA signatures and their diagnostic/prognostic properties.
A clear conclusion on which quantitation method is more suitable cannot be drawn with the currently avail-
able data. The use of multiple internal controls or the geometric mean, using a multiplex screening method, such 
as microarrays or next generation sequencing, would provide the optimal means of normalisation. Alternatively, 
the NanoString nCounter technology enables profiling of around 800 molecular targets in one single reaction by 
utilising molecular “barcodes”. This approach normalises the data by using multiple targets, and more importantly 
quantifies multiple miRNAs which can be used simultaneously as biomarkers to improve detection accuracy. In 
addition, this platform overcomes the need for data processing and bioinformatic analysis expertise, as in the case 
of microarrays or high-throughput sequencing, thus may be easily utilised in a clinical setting46.
To evaluate the potential detection efficiency for each individual miRNA, individual miRNAs reported in more 
than one study were grouped to evaluate its detection accuracy. In this meta-analysis, miR-21 and miR-92a were 
the most commonly reported faecal-based miRNAs (Table 6). Numerous studies have characterised the functional 
roles of these two miRNAs in CRC pathogenesis and aggressiveness. Up-regulation of miR-21 and miR-92a pro-
motes CRC cell migration, invasion and proliferation11,16,18,20,22, and inhibition of apoptosis49–51. Several signifi-
cant targets of miR-21 are associated with CRC malignancy, such as phosphatase and tensin homolog (PTEN)49,52, 
miRNA
No. of 
Studies AUC
Partial 
AUC
log DOR 
(95% CI)
DOR  
(95% CI)
Sensitivity 
(95% CI)
Specificity 
(95% CI)
+LR  
(95% CI)
−LR  
(95% CI)
Staging# (Based on the data from the included studies)
Early 11 0.753 0.582 1.72 (1.29–2.15)
5.58 
(3.62–8.62)
57.0% 
(44.4–68.8%)
80.0% 
(71.1–86.7%)
2.68 
(2.10–3.43)
0.54 
(0.43–0.68)
Late 11 0.787 0.627 1.90 (1.47–2.34)
6.70  
(4.34–10.36)
62.1% 
(47.8–74.6%)
80.0% 
(71.1–86.7%)
2.82 
(2.22–3.59)
0.45 
(0.33–0.61)
Tumour location (Based on the data from the included studies)
Proximal 9 0.719 0.488 1.23 (0.93–1.54)
3.44 
(2.53–4.66)
39.8% 
(21.8–61.0%)
82.4% 
(71.5–89.7%)
2.08 
(1.76–2.44)
0.75 
(0.64–0.88)
Distal 9 0.818 0.675 2.14 (1.60–2.68)
8.51 
(4.97–14.57)
64.1% 
(43.9–80.3%)
81.9% 
(71.5–89.1%)
3.04 
(2.31–4.01)
0.41 
(0.28–0.61)
Table 5. Subgroup analysis for pooled microRNAs in association with CRC staging and tumour location. DOR, 
Diagnostic odds ratio; +LR, Positive likelihood ratio; −LR, Negative likelihood ratio. #Early stage CRC includes 
TNM stages 0 + I + II or Dukes’ stage A + B; Late stage CRC includes CRC stages III + IV or Dukes’ stage C + D.
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programmed cell death protein 4 (PDCD4)53,54, and ras homolog gene family member B (RhoB)55. Among these, 
PTEN was reported frequently silenced in CRC by miR-21, resulting in PI3K/AKT pathway activation and induc-
tion of tumour formation49,52. Recently, a long non-coding RNA (LINC00312) suppressed in CRC was shown to 
regulate miR-21 levels through its function as a miRNA sponge, thereby regulating PTEN expression56. miR-92a has 
been shown to disrupt the expression of several tumour suppressors such as PTEN57,58, Dickkopf WNT Signalling 
Pathway Inhibitor 3 (DKK3)57, Kruppel-like factor 4 (KLF4)59 and mothers against decapentaplegic homolog 7 
(SMAD7)60. Hence, miR-92a activates the PI3K/AKT, WNT/β-catenin and BMP/Smad pathways and enhances 
miRNA Diagnosis
No. of 
Studies AUC
Partial 
AUC
log DOR 
(95% CI)
DOR  
(95% CI)
Sensitivity 
(95% CI)
Specificity  
(95% CI)
+LR  
(95% CI)
−LR  
(95% CI)
miR-21
Adenoma 3 0.771 0.598 1.96 (1.96–3.23)
7.10 
(1.99–25.34)
59.6% 
(27.7–85.0%)
83.0% 
(47.2–96.4%)
2.97 
(1.45–6.07)
0.49 
(0.27–0.90)
CRC 5 0.843 0.549 2.23 (1.09–3.37)
9.28 
(2.97–28.97)
59.3% 
(26.3–85.6%)
85.6% 
(72.2–93.2%)
3.38 
(2.07–5.53)
0.43 
(0.28–0.68)
miR-21-related combination CRC 4 0.843 0.764 2.82 (1.95–3.69)
16.73 
(7.00–39.94)
75.7% 
(60.3–86.5%)
85.0% 
(55.1–96.3%)
4.31 
(2.22–8.39)
0.31 
(0.20–0.46)
miR-92a
Adenoma 2 0.635 0.467 1.96 (0.36–3.55)
7.08 
(1.43–34.97)
43.2% 
(20.1–69.8%)
91.0% 
(41.6–99.3%)
4.70 
(0.80–27.60)
0.66 
(0.54–0.81)
CRC 4 0.794 0.537 2.15 (1.19–3.10)
8.57 
(3.30–22.27)
46.8% 
(26.3–68.4%)
90.5% 
77.1–96.4%)
4.53 
(2.17–9.43)
0.57 
(0.41–0.81)
miR-92a-related combination CRC 5 0.791 0.685 2.35 (1.87–2.83)
10.47 
(6.46–16.98)
68.2% 
(56.8–77.7%)
83.7% 
(65.9–93.2%)
3.71 
(2.44–5.64)
0.40 
(0.33–0.49)
miR-21 + miR-92a CRC 9 0.837 0.548 2.19 (1.48–2.91)
8.97 
(4.39–18.29)
53.7% 
(33.4–74.8%)
87.8% 
(79.5–93.0%)
3.68 
(2.54–5.33)
0.51 
(0.40–0.65)
miR-20a CRC 2 0.797 0.367 1.35 (0.56–2.15)
3.87 
(1.75–8.55)
34.4% 
(9.0–73.6%)
87.5% 
(73.6–94.6%)
2.84 
(2.13–3.80)
0.70 
(0.44–1.13)
miR-106a CRC 2 0.416 0.356 3.38 (2.05–4.71)
29.33  
(7.74–111.11)
36.1% 
(30.4–42.2%)
98.0% 
(94.7–99.2%)
18.85 
(5.44–65.35)
0.65 
(0.59–0.72)
miR-135b CRC 2 0.798 0.656 2.32 (1.59–3.05)
10.18 
(4.91–21.09)
63.1% 
29.4–87.5%)
86.2% 
(41.8–98.2%)
4.44 
(1.23–16.09)
0.44 
(0.26–0.77)
miR-223 CRC 2 0.777 0684 2.69 (-0.42–5.79)
14.69  
(0.66–328.44)
67.9% 
(47.9–83.0%)
87.4% 
(39.3–98.7%)
5.43 
(0.56–52.59)
0.41 
(0.18–0.92)
Table 6. Diagnostic accuracy of individual microRNAs and microRNA combinations. DOR, Diagnostic odds 
ratio; +LR, Positive likelihood ratio; −LR, Negative likelihood ratio.
Figure 5. Diagnostic accuracy in pooled miR-21 and miR-92a. (A) SROC for pooled miR-21 in the detection 
of CRC (n = 5) and colonic adenoma (n = 3). (B) SROC for pooled miR-92a in the detection of CRC (n = 4) 
and colonic adenoma (n = 2). The number next to the dot/triangle corresponding to the study ID in Table 1 
(Blue dots: CRC) or Table 2 (Red triangles: colonic adenoma). Sen, sensitivity; Spe, specificity; SOP, summary 
operating point. The circular regions (95% confidence contour) contain likely combinations of the mean value 
of sensitivity and specificity.
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tumorigenesis. Subject to this analysis five studies reported the use of miR-21 in the identification of CRC, and three 
studies reported its use in identification of adenomas11,16,18,20,22. Four studies reported the utility of miR-92a in the 
identification of CRC, and two studies in identification of adenomas11,17,20,22. miR-21 had a better detection accuracy 
range compared with miR-92a, with a DOR of 9.28 (95% CI: 2.97–28.97) and summary AUC of 0.843. Panels includ-
ing a combination of either miR-21 or miR-92a, as well as panels including both miR-21 and miR-92a demonstrated 
a small improvement in detection (Fig. 5 and Table 6). However, due to the small number of published studies, with 
each having wide confidence intervals, a direct comparison between two faecal-based miRNAs may not be accurate. 
Additional data are needed to limit potential errors.
The FOBT or FIT, have limited sensitivity for detecting proximal compared with distal CRC61,62. This is due to the 
degradation of haemoglobin. Hence, tumour location analysis for faecal-based miRNA detection was also considered 
and reported by several studies – with none of them reporting a statistical difference. In this study, the results between 
pooled miRNAs for proximal and distal CRC reveal differences associated with tumour location, with an AUC of 0.719 
versus 0.818, and DOR of 3.44 (95% CI: 2.53–4.66) versus 8.51 (95% CI: 4.97–14.57) (Fig. 4B and Table 5).
Our study is characterised by many strengths but should be interpreted in the context of specific shortcomings. 
Firstly, subgroup analysis suggested that the combination of faecal miRNAs exhibited a good accuracy for CRC and 
colonic adenoma patients screening (Tables 3, 4 and Fig. 3). However, certain combinations of miRNAs may not 
significantly improve the detection accuracy. For example, the panel containing miR-223, miR-92a, miR-16 and 
miR-106b had a sensitivity of 73.9%, specificity of 82.2% and AUC of 0.8413, whereas the combination of miR-18a 
and miR-135b only had a sensitivity of 66%, specificity of 72% and AUC of 0.7526. Therefore, an optimal miRNA 
combination panel should be prioritised. Secondly, the majority of studies were performed in East Asia (Hong Kong, 
Taiwan, China, Japan and Singapore) (Table 1) with only one study in the USA, Europe and the Middle East, making 
it unclear whether the ethnic background of participants has an influence on the expression of miRNAs in CRC. 
Thirdly, due to the high cost of colonoscopy, the majority of test subjects were recruited from the corresponding 
clinics. This may result in a degree of bias, since the subjects are not representative of the general population. Last but 
not least, the publication bias analysis revealed that pooled miRNAs in CRC have a significant asymmetry (P = 0.03). 
This may be due to file-drawer effects, bias from the studies with small same sizes, lack of clarity in reporting the 
results for some publications, or the level of detail provided being lower than the one required for our analysis. 
Consequently, some studies were excluded, resulting in a possible bias in our meta-analysis (Fig. 6A).
In conclusion, faecal-based miRNAs show a relatively high accuracy for the non-invasive detection of colonic 
adenomas and CRC in the studied population. The use of a panel of miRNAs as biomarkers may result in a higher 
CRC detection rate, while the combination of miRNA biomarkers with FOBT or FIT may increase the detection 
accuracy. Large, ideally multi-centre, double-blinded randomised controlled trials are needed to establish the 
value of miRNAs as biomarkers in CRC screening within the general population.
Methods
overview. The study protocol followed the Cochrane Handbook for Diagnostic Test Accuracy Review63 and 
the Preferred Reporting Items in Systematic Reviews and the Meta-Analysis statement (PRISMA)64. Investigators 
of each of the original studies obtained approval from their local ethics committee and had written, informed 
patient consent.
Literature search strategy. The search strategy was designed to identify any studies describing the diag-
nostic value of faecal-based miRNA for CRC and colonic adenoma patients. After an initial search for articles in 
PubMed, assessments of key terms within the title and abstract were conducted. A full systematic search using the 
established key terms was adopted for the following databases: PubMed, Ovid Embase, The Cochrane Library, 
Scopus and Web of Science. The search terms used were “miRNA OR microRNA OR miR” AND “colorectal 
Figure 6. Deeks’ funnel plot asymmetry test for the assessment of potential bias in microRNA assays. (A) 
Pooled miRNAs for CRC and, (B) Pooled miRNAs for colonic adenoma.
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cancer OR colorectal tumor OR colorectal adenocarcinoma OR colorectal carcinoma OR colorectal neoplasm 
OR colon cancer OR colonic adenoma OR colonic adenocarcinoma OR stomach cancer OR rectal cancer OR 
CRC” AND “stool OR feces”. The search formulas are available as supplementary data (Supplementary data 1). 
Manual searching of related citations and reference lists was undertaken. Book chapters, letters to editors, com-
mentaries, editorials, patents, and non-peer reviewed articles were excluded. Two investigators independently 
screened the search results, initially through articles’ title and abstract. The filtered candidate articles were then 
scrutinised independently through full-text reading. Discrepancies were resolved through discussion between 
the two investigators.
study selection criteria. All research articles in any language published up to November 17, 2017 were eli-
gible for inclusion. An electronic data extraction form was developed, and pre-tested, with data extracted by two 
researchers. Eligible studies included in this meta-analysis adhered to the following criteria: (1) studies evaluated 
the diagnostic value of miRNAs for detecting human CRC or colonic adenomas; (2) all CRC patients involved 
in the study had been confirmed by histology; (3) studies contained data on miRNAs’ sensitivity, specificity, and 
sample size to enable reconstruction of the diagnostic 2 × 2 contingency table. Exclusion criteria were set as fol-
lows: (1) duplicated studies, the later ones were excluded; (2) publications that were unrelated to the diagnostic 
value of miRNAs for CRC; (3) incomplete data reporting. The detection accuracy of miRNAs between proximal 
(from cecum to transverse colon) and distal (from splenic flexure to rectum) CRC, as well as between early (CRC 
stages 0 + I + II or Dukes’ stages A + B) and late (CRC stages III + IV or Dukes’ stages C + D) stage CRC were 
evaluated separately if investigators reported the location and stage. Each individual miRNA and miRNA combi-
nations were grouped together if found in more than two studies.
Risk of bias. The Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2) was utilised to assess 
the quality of included publications, evaluating four key domains (“Patient Selection”, “Index Test”, “Reference 
Standard”, and “Flow and Timing”) in two categories (risk of bias and applicability of diagnostic accuracy studies)30. 
Each category in all publications was judged as low, high or unclear based on the assessment criteria provided. 
Assessment of each included study was performed by two investigators, with disagreements resolved by consen-
sus after discussion.
Data synthesis. A meta-analysis of diagnostic test accuracy was conducted on faecal-based non-invasive 
miRNA tests through a bivariate random effects modelling approach. The bivariate model accounts for the corre-
lation between the studies’ sensitivity and specificity in two different levels. The first level represents a variability 
between sensitivity and specificity within one study; the second level represents the heterogeneity in diagnostic 
performance of the index test across the testing studies. Random effects meta-analysis methods were applied in 
our study as heterogeneity is presumed to exist.
Statistical analyses in this study were performed using the statistical package mada version 0.4.8 in R (version 
3.4.3) to implement the bivariate normal approach of Reitsma et al.65. Sensitivity, specificity, diagnostic odds ratio 
(DOR), log DOR, positive likelihood ratio (+LR) and negative likelihood ratio (–LR) were calculated along with 
their 95% confidence interval (95% CI) based on the random effects model (DerSimonian and Laird method) 
with continuity correction66,67. Summary receiver operating characteristic (sROC) curves, area under the curve 
(AUC) and partial AUC were also utilised to examine the pooled faecal-based miRNAs in CRC, adenoma and 
the subgroups. Potential sources of heterogeneity were investigated using subgroup and bivariate meta-regression 
(restricted maximum likelihood (REML) estimators) analysis. The Deeks’ funnel plot asymmetry test was exam-
ined using the midas package in Stata (version 12).
Interpretation of diagnostic test accuracy statistics. The AUC was interpreted in four-grades: >0.97, 
excellent; 0.93–0.96, very good; 0.75–0.92, good; < 0.75, not accurate68. The values of –LR and +LR were also 
divided into four categories. The –LR values < 0.1, 0.1–0.2, 0.2–0.5 and >0.5 were identified as large, moderate, 
small and not meaningful decreases in probability, respectively69. The +LR values >10, 5–10, 2–5 and <2 were 
classified as large, moderate, small and not meaningful increases in probability, respectively69. P < 0.05 was con-
sidered statistically significant.
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